This pipeline uses various statistical tests to identify miRs whose log2 expression levels correlated to selected clinical features.
Testing the association between 498 miRs and 12 clinical features across 993 samples, statistically thresholded by P value < 0.05 and Q value < 0.3, 10 clinical features related to at least one miRs.
-
6 miRs correlated to 'Time to Death'.
-
HSA-MIR-874 , HSA-MIR-30A , HSA-MIR-328 , HSA-MIR-1307 , HSA-MIR-99B , ...
-
54 miRs correlated to 'AGE'.
-
HSA-MIR-424 , HSA-MIR-31 , HSA-MIR-99A , HSA-MIR-381 , HSA-MIR-598 , ...
-
46 miRs correlated to 'NEOPLASM.DISEASESTAGE'.
-
HSA-MIR-210 , HSA-MIR-374C , HSA-MIR-301A , HSA-MIR-143 , HSA-MIR-455 , ...
-
11 miRs correlated to 'PATHOLOGY.T.STAGE'.
-
HSA-MIR-758 , HSA-MIR-127 , HSA-MIR-9-2 , HSA-MIR-150 , HSA-MIR-9-1 , ...
-
9 miRs correlated to 'PATHOLOGY.N.STAGE'.
-
HSA-MIR-10A , HSA-MIR-3613 , HSA-MIR-455 , HSA-MIR-92A-2 , HSA-MIR-577 , ...
-
109 miRs correlated to 'PATHOLOGY.M.STAGE'.
-
HSA-MIR-16-1 , HSA-MIR-628 , HSA-MIR-424 , HSA-MIR-3170 , HSA-MIR-550A-2 , ...
-
393 miRs correlated to 'HISTOLOGICAL.TYPE'.
-
HSA-MIR-210 , HSA-MIR-1306 , HSA-MIR-130B , HSA-MIR-301A , HSA-MIR-197 , ...
-
37 miRs correlated to 'RADIATIONS.RADIATION.REGIMENINDICATION'.
-
HSA-MIR-3605 , HSA-MIR-3607 , HSA-MIR-1271 , HSA-MIR-940 , HSA-MIR-3647 , ...
-
12 miRs correlated to 'NUMBER.OF.LYMPH.NODES'.
-
HSA-MIR-577 , HSA-MIR-10A , HSA-MIR-3613 , HSA-MIR-221 , HSA-MIR-92A-2 , ...
-
105 miRs correlated to 'RACE'.
-
HSA-MIR-660 , HSA-MIR-1304 , HSA-MIR-20A , HSA-MIR-93 , HSA-MIR-103-1 , ...
-
No miRs correlated to 'GENDER', and 'ETHNICITY'.
Complete statistical result table is provided in Supplement Table 1
Table 1. Get Full Table This table shows the clinical features, statistical methods used, and the number of miRs that are significantly associated with each clinical feature at P value < 0.05 and Q value < 0.3.
Clinical feature | Statistical test | Significant miRs | Associated with | Associated with | ||
---|---|---|---|---|---|---|
Time to Death | Cox regression test | N=6 | shorter survival | N=5 | longer survival | N=1 |
AGE | Spearman correlation test | N=54 | older | N=9 | younger | N=45 |
NEOPLASM DISEASESTAGE | Kruskal-Wallis test | N=46 | ||||
PATHOLOGY T STAGE | Spearman correlation test | N=11 | higher stage | N=3 | lower stage | N=8 |
PATHOLOGY N STAGE | Spearman correlation test | N=9 | higher stage | N=1 | lower stage | N=8 |
PATHOLOGY M STAGE | Kruskal-Wallis test | N=109 | ||||
GENDER | Wilcoxon test | N=0 | ||||
HISTOLOGICAL TYPE | Kruskal-Wallis test | N=393 | ||||
RADIATIONS RADIATION REGIMENINDICATION | Wilcoxon test | N=37 | yes | N=37 | no | N=0 |
NUMBER OF LYMPH NODES | Spearman correlation test | N=12 | higher number.of.lymph.nodes | N=1 | lower number.of.lymph.nodes | N=11 |
RACE | Kruskal-Wallis test | N=105 | ||||
ETHNICITY | Wilcoxon test | N=0 |
Table S1. Basic characteristics of clinical feature: 'Time to Death'
Time to Death | Duration (Months) | 0-234.3 (median=21.4) |
censored | N = 858 | |
death | N = 114 | |
Significant markers | N = 6 | |
associated with shorter survival | 5 | |
associated with longer survival | 1 |
Table S2. Get Full Table List of 6 miRs significantly associated with 'Time to Death' by Cox regression test
HazardRatio | Wald_P | Q | C_index | |
---|---|---|---|---|
HSA-MIR-874 | 1.5 | 1.304e-05 | 0.0065 | 0.586 |
HSA-MIR-30A | 0.77 | 6.289e-05 | 0.031 | 0.379 |
HSA-MIR-328 | 1.37 | 9.714e-05 | 0.048 | 0.586 |
HSA-MIR-1307 | 1.35 | 0.0001386 | 0.069 | 0.621 |
HSA-MIR-99B | 1.46 | 0.0003144 | 0.16 | 0.586 |
HSA-MIR-148B | 1.5 | 0.0004165 | 0.21 | 0.581 |
Table S3. Basic characteristics of clinical feature: 'AGE'
AGE | Mean (SD) | 58.66 (13) |
Significant markers | N = 54 | |
pos. correlated | 9 | |
neg. correlated | 45 |
Table S4. Get Full Table List of top 10 miRs significantly correlated to 'AGE' by Spearman correlation test
SpearmanCorr | corrP | Q | |
---|---|---|---|
HSA-MIR-424 | -0.2092 | 3.708e-11 | 1.85e-08 |
HSA-MIR-31 | -0.2111 | 6.072e-11 | 3.02e-08 |
HSA-MIR-99A | -0.2024 | 1.629e-10 | 8.08e-08 |
HSA-MIR-381 | -0.1941 | 9.348e-10 | 4.63e-07 |
HSA-MIR-598 | -0.1903 | 1.91e-09 | 9.43e-07 |
HSA-MIR-652 | -0.1842 | 6.351e-09 | 3.13e-06 |
HSA-LET-7C | -0.1771 | 2.37e-08 | 1.17e-05 |
HSA-MIR-542 | -0.1692 | 9.875e-08 | 4.85e-05 |
HSA-MIR-125B-1 | -0.1607 | 4.273e-07 | 0.000209 |
HSA-MIR-202 | -0.1954 | 6.796e-07 | 0.000332 |
Table S5. Basic characteristics of clinical feature: 'NEOPLASM.DISEASESTAGE'
NEOPLASM.DISEASESTAGE | Labels | N |
STAGE I | 80 | |
STAGE IA | 79 | |
STAGE IB | 10 | |
STAGE II | 9 | |
STAGE IIA | 335 | |
STAGE IIB | 223 | |
STAGE III | 2 | |
STAGE IIIA | 136 | |
STAGE IIIB | 26 | |
STAGE IIIC | 58 | |
STAGE IV | 16 | |
STAGE TIS | 1 | |
STAGE X | 17 | |
Significant markers | N = 46 |
Table S6. Get Full Table List of top 10 miRs differentially expressed by 'NEOPLASM.DISEASESTAGE'
ANOVA_P | Q | |
---|---|---|
HSA-MIR-210 | 9.842e-09 | 4.9e-06 |
HSA-MIR-374C | 3.241e-06 | 0.00161 |
HSA-MIR-301A | 5.311e-06 | 0.00263 |
HSA-MIR-143 | 6.606e-06 | 0.00327 |
HSA-MIR-455 | 6.644e-06 | 0.00328 |
HSA-MIR-130B | 7.034e-06 | 0.00347 |
HSA-LET-7F-2 | 8.67e-06 | 0.00427 |
HSA-MIR-1247 | 1.569e-05 | 0.0077 |
HSA-MIR-484 | 1.706e-05 | 0.00836 |
HSA-MIR-222 | 1.73e-05 | 0.00846 |
Table S7. Basic characteristics of clinical feature: 'PATHOLOGY.T.STAGE'
PATHOLOGY.T.STAGE | Mean (SD) | 1.92 (0.72) |
N | ||
1 | 263 | |
2 | 576 | |
3 | 115 | |
4 | 36 | |
Significant markers | N = 11 | |
pos. correlated | 3 | |
neg. correlated | 8 |
Table S8. Get Full Table List of top 10 miRs significantly correlated to 'PATHOLOGY.T.STAGE' by Spearman correlation test
SpearmanCorr | corrP | Q | |
---|---|---|---|
HSA-MIR-758 | -0.1506 | 1.999e-06 | 0.000995 |
HSA-MIR-127 | -0.1255 | 7.465e-05 | 0.0371 |
HSA-MIR-9-2 | 0.1183 | 0.0001911 | 0.0948 |
HSA-MIR-150 | -0.117 | 0.0002253 | 0.112 |
HSA-MIR-9-1 | 0.1159 | 0.0002574 | 0.127 |
HSA-MIR-382 | -0.1158 | 0.0002627 | 0.13 |
HSA-MIR-409 | -0.1153 | 0.0002805 | 0.138 |
HSA-MIR-411 | -0.1155 | 0.0003019 | 0.148 |
HSA-MIR-3662 | 0.1456 | 0.0003397 | 0.166 |
HSA-MIR-181C | -0.1117 | 0.0004284 | 0.21 |
Table S9. Basic characteristics of clinical feature: 'PATHOLOGY.N.STAGE'
PATHOLOGY.N.STAGE | Mean (SD) | 0.77 (0.91) |
N | ||
0 | 470 | |
1 | 329 | |
2 | 109 | |
3 | 68 | |
Significant markers | N = 9 | |
pos. correlated | 1 | |
neg. correlated | 8 |
Table S10. Get Full Table List of 9 miRs significantly correlated to 'PATHOLOGY.N.STAGE' by Spearman correlation test
SpearmanCorr | corrP | Q | |
---|---|---|---|
HSA-MIR-10A | 0.1558 | 1.001e-06 | 0.000499 |
HSA-MIR-3613 | -0.1319 | 3.586e-05 | 0.0178 |
HSA-MIR-455 | -0.1283 | 5.859e-05 | 0.0291 |
HSA-MIR-92A-2 | -0.1283 | 5.863e-05 | 0.0291 |
HSA-MIR-577 | -0.1389 | 0.0001132 | 0.0559 |
HSA-MIR-17 | -0.1143 | 0.000346 | 0.171 |
HSA-MIR-19B-1 | -0.1115 | 0.000504 | 0.248 |
HSA-MIR-548B | -0.1272 | 0.0005354 | 0.263 |
HSA-MIR-19B-2 | -0.1106 | 0.00054 | 0.265 |
Table S11. Basic characteristics of clinical feature: 'PATHOLOGY.M.STAGE'
PATHOLOGY.M.STAGE | Labels | N |
CM0 (I+) | 2 | |
M0 | 843 | |
M1 | 16 | |
MX | 132 | |
Significant markers | N = 109 |
Table S12. Get Full Table List of top 10 miRs differentially expressed by 'PATHOLOGY.M.STAGE'
ANOVA_P | Q | |
---|---|---|
HSA-MIR-16-1 | 3.068e-12 | 1.53e-09 |
HSA-MIR-628 | 2.232e-09 | 1.11e-06 |
HSA-MIR-424 | 1.847e-08 | 9.16e-06 |
HSA-MIR-3170 | 4.332e-08 | 2.14e-05 |
HSA-MIR-550A-2 | 6.214e-08 | 3.07e-05 |
HSA-MIR-3607 | 9.118e-08 | 4.5e-05 |
HSA-MIR-345 | 2.061e-07 | 0.000101 |
HSA-MIR-23B | 3.009e-07 | 0.000148 |
HSA-MIR-361 | 3.905e-07 | 0.000191 |
HSA-MIR-3174 | 5.152e-07 | 0.000252 |
Table S13. Basic characteristics of clinical feature: 'GENDER'
GENDER | Labels | N |
FEMALE | 982 | |
MALE | 11 | |
Significant markers | N = 0 |
Table S14. Basic characteristics of clinical feature: 'HISTOLOGICAL.TYPE'
HISTOLOGICAL.TYPE | Labels | N |
INFILTRATING CARCINOMA NOS | 1 | |
INFILTRATING DUCTAL CARCINOMA | 735 | |
INFILTRATING LOBULAR CARCINOMA | 165 | |
MEDULLARY CARCINOMA | 5 | |
MIXED HISTOLOGY (PLEASE SPECIFY) | 28 | |
MUCINOUS CARCINOMA | 14 | |
OTHER SPECIFY | 44 | |
Significant markers | N = 393 |
Table S15. Get Full Table List of top 10 miRs differentially expressed by 'HISTOLOGICAL.TYPE'
ANOVA_P | Q | |
---|---|---|
HSA-MIR-210 | 1.176e-40 | 5.86e-38 |
HSA-MIR-1306 | 1.238e-33 | 6.15e-31 |
HSA-MIR-130B | 6.44e-33 | 3.19e-30 |
HSA-MIR-301A | 2.101e-32 | 1.04e-29 |
HSA-MIR-197 | 7.001e-32 | 3.46e-29 |
HSA-MIR-328 | 1.129e-31 | 5.57e-29 |
HSA-MIR-505 | 2.187e-31 | 1.08e-28 |
HSA-MIR-616 | 5.565e-31 | 2.73e-28 |
HSA-MIR-301B | 7.534e-31 | 3.69e-28 |
HSA-MIR-186 | 9.976e-31 | 4.88e-28 |
37 miRs related to 'RADIATIONS.RADIATION.REGIMENINDICATION'.
Table S16. Basic characteristics of clinical feature: 'RADIATIONS.RADIATION.REGIMENINDICATION'
RADIATIONS.RADIATION.REGIMENINDICATION | Labels | N |
NO | 278 | |
YES | 715 | |
Significant markers | N = 37 | |
Higher in YES | 37 | |
Higher in NO | 0 |
Table S17. Get Full Table List of top 10 miRs differentially expressed by 'RADIATIONS.RADIATION.REGIMENINDICATION'
W(pos if higher in 'YES') | wilcoxontestP | Q | AUC | |
---|---|---|---|---|
HSA-MIR-3605 | 70216 | 5.313e-10 | 2.65e-07 | 0.6285 |
HSA-MIR-3607 | 74547 | 9.293e-10 | 4.62e-07 | 0.625 |
HSA-MIR-1271 | 74602 | 5.432e-07 | 0.000269 | 0.6038 |
HSA-MIR-940 | 74171 | 1.885e-06 | 0.000933 | 0.5991 |
HSA-MIR-3647 | 80330 | 2.654e-06 | 0.00131 | 0.5959 |
HSA-MIR-551B | 58147 | 4.088e-06 | 0.00202 | 0.6012 |
HSA-MIR-3620 | 9498 | 4.163e-06 | 0.00205 | 0.6541 |
HSA-MIR-3677 | 80556 | 6.926e-06 | 0.0034 | 0.5919 |
HSA-MIR-101-2 | 117574 | 7.378e-06 | 0.00362 | 0.5915 |
HSA-MIR-3928 | 70619 | 8.127e-06 | 0.00397 | 0.5943 |
Table S18. Basic characteristics of clinical feature: 'NUMBER.OF.LYMPH.NODES'
NUMBER.OF.LYMPH.NODES | Mean (SD) | 2.33 (4.6) |
Significant markers | N = 12 | |
pos. correlated | 1 | |
neg. correlated | 11 |
Table S19. Get Full Table List of top 10 miRs significantly correlated to 'NUMBER.OF.LYMPH.NODES' by Spearman correlation test
SpearmanCorr | corrP | Q | |
---|---|---|---|
HSA-MIR-577 | -0.1634 | 2.264e-05 | 0.0113 |
HSA-MIR-10A | 0.1423 | 3.519e-05 | 0.0175 |
HSA-MIR-3613 | -0.1362 | 7.608e-05 | 0.0377 |
HSA-MIR-221 | -0.1291 | 0.0001775 | 0.0879 |
HSA-MIR-92A-2 | -0.1266 | 0.0002365 | 0.117 |
HSA-MIR-222 | -0.1265 | 0.0002381 | 0.117 |
HSA-MIR-29A | -0.1233 | 0.0003437 | 0.169 |
HSA-MIR-197 | -0.1232 | 0.0003468 | 0.17 |
HSA-MIR-2114 | -0.1546 | 0.0003617 | 0.177 |
HSA-LET-7G | -0.1214 | 0.0004255 | 0.208 |
Table S20. Basic characteristics of clinical feature: 'RACE'
RACE | Labels | N |
AMERICAN INDIAN OR ALASKA NATIVE | 1 | |
ASIAN | 57 | |
BLACK OR AFRICAN AMERICAN | 138 | |
WHITE | 709 | |
Significant markers | N = 105 |
Table S21. Get Full Table List of top 10 miRs differentially expressed by 'RACE'
ANOVA_P | Q | |
---|---|---|
HSA-MIR-660 | 2.079e-16 | 1.04e-13 |
HSA-MIR-1304 | 3.098e-16 | 1.54e-13 |
HSA-MIR-20A | 4.23e-13 | 2.1e-10 |
HSA-MIR-93 | 1.119e-12 | 5.54e-10 |
HSA-MIR-103-1 | 4.587e-11 | 2.27e-08 |
HSA-MIR-17 | 5.524e-11 | 2.72e-08 |
HSA-MIR-361 | 7.203e-11 | 3.54e-08 |
HSA-MIR-185 | 9.8e-11 | 4.81e-08 |
HSA-MIR-500B | 1.089e-10 | 5.34e-08 |
HSA-MIR-128-2 | 3.682e-10 | 1.8e-07 |
-
Expresson data file = BRCA-TP.miRseq_RPKM_log2.txt
-
Clinical data file = BRCA-TP.merged_data.txt
-
Number of patients = 993
-
Number of miRs = 498
-
Number of clinical features = 12
For survival clinical features, Wald's test in univariate Cox regression analysis with proportional hazards model (Andersen and Gill 1982) was used to estimate the P values using the 'coxph' function in R. Kaplan-Meier survival curves were plot using the four quartile subgroups of patients based on expression levels
For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R
For multi-class clinical features (ordinal or nominal), one-way analysis of variance (Howell 2002) was applied to compare the log2-expression levels between different clinical classes using 'anova' function in R
For two-class clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the log2-expression levels between the two clinical classes using 't.test' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.